Global Prostate Cancer Nuclear Medicine Diagnostics Market Size, Status and Forecast 2023-2027

Report ID: 950197 | Published Date: Jan 2025 | No. of Page: 109 | Base Year: 2024 | Rating: 3.7 | Webstory: Check our Web story
Request Sample Report
Pre-Order Enquiry
Request Discount(%) 
1 Report Overview
    1.1 Study Scope
    1.2 Market Analysis by Type
        1.2.1 Global Prostate Cancer Nuclear Medicine Diagnostics Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
        1.2.2 SPECT
        1.2.3 PET
    1.3 Market by Application
        1.3.1 Global Prostate Cancer Nuclear Medicine Diagnostics Market Share by Application: 2016 VS 2021 VS 2027
        1.3.2 Hospitals
        1.3.3 Clinics
        1.3.4 Others
    1.4 Study Objectives
    1.5 Years Considered

2 Global Growth Trends
    2.1 Global Prostate Cancer Nuclear Medicine Diagnostics Market Perspective (2016-2027)
    2.2 Prostate Cancer Nuclear Medicine Diagnostics Growth Trends by Regions
        2.2.1 Prostate Cancer Nuclear Medicine Diagnostics Market Size by Regions: 2016 VS 2021 VS 2027
        2.2.2 Prostate Cancer Nuclear Medicine Diagnostics Historic Market Share by Regions (2016-2021)
        2.2.3 Prostate Cancer Nuclear Medicine Diagnostics Forecasted Market Size by Regions (2022-2027)
    2.3 Prostate Cancer Nuclear Medicine Diagnostics Industry Dynamic
        2.3.1 Prostate Cancer Nuclear Medicine Diagnostics Market Trends
        2.3.2 Prostate Cancer Nuclear Medicine Diagnostics Market Drivers
        2.3.3 Prostate Cancer Nuclear Medicine Diagnostics Market Challenges
        2.3.4 Prostate Cancer Nuclear Medicine Diagnostics Market Restraints

3 Competition Landscape by Key Players
    3.1 Global Top Prostate Cancer Nuclear Medicine Diagnostics Players by Revenue
        3.1.1 Global Top Prostate Cancer Nuclear Medicine Diagnostics Players by Revenue (2016-2021)
        3.1.2 Global Prostate Cancer Nuclear Medicine Diagnostics Revenue Market Share by Players (2016-2021)
    3.2 Global Prostate Cancer Nuclear Medicine Diagnostics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
    3.3 Players Covered: Ranking by Prostate Cancer Nuclear Medicine Diagnostics Revenue
    3.4 Global Prostate Cancer Nuclear Medicine Diagnostics Market Concentration Ratio
        3.4.1 Global Prostate Cancer Nuclear Medicine Diagnostics Market Concentration Ratio (CR5 and HHI)
        3.4.2 Global Top 10 and Top 5 Companies by Prostate Cancer Nuclear Medicine Diagnostics Revenue in 2020
    3.5 Prostate Cancer Nuclear Medicine Diagnostics Key Players Head office and Area Served
    3.6 Key Players Prostate Cancer Nuclear Medicine Diagnostics Product Solution and Service
    3.7 Date of Enter into Prostate Cancer Nuclear Medicine Diagnostics Market
    3.8 Mergers & Acquisitions, Expansion Plans

4 Prostate Cancer Nuclear Medicine Diagnostics Breakdown Data by Type
    4.1 Global Prostate Cancer Nuclear Medicine Diagnostics Historic Market Size by Type (2016-2021)
    4.2 Global Prostate Cancer Nuclear Medicine Diagnostics Forecasted Market Size by Type (2022-2027)

5 Prostate Cancer Nuclear Medicine Diagnostics Breakdown Data by Application
    5.1 Global Prostate Cancer Nuclear Medicine Diagnostics Historic Market Size by Application (2016-2021)
    5.2 Global Prostate Cancer Nuclear Medicine Diagnostics Forecasted Market Size by Application (2022-2027)

6 North America
    6.1 North America Prostate Cancer Nuclear Medicine Diagnostics Market Size (2016-2027)
    6.2 North America Prostate Cancer Nuclear Medicine Diagnostics Market Size by Type
        6.2.1 North America Prostate Cancer Nuclear Medicine Diagnostics Market Size by Type (2016-2021)
        6.2.2 North America Prostate Cancer Nuclear Medicine Diagnostics Market Size by Type (2022-2027)
        6.2.3 North America Prostate Cancer Nuclear Medicine Diagnostics Market Size by Type (2016-2027)
    6.3 North America Prostate Cancer Nuclear Medicine Diagnostics Market Size by Application
        6.3.1 North America Prostate Cancer Nuclear Medicine Diagnostics Market Size by Application (2016-2021)
        6.3.2 North America Prostate Cancer Nuclear Medicine Diagnostics Market Size by Application (2022-2027)
        6.3.3 North America Prostate Cancer Nuclear Medicine Diagnostics Market Size by Application (2016-2027)
    6.4 North America Prostate Cancer Nuclear Medicine Diagnostics Market Size by Country
        6.4.1 North America Prostate Cancer Nuclear Medicine Diagnostics Market Size by Country (2016-2021)
        6.4.2 North America Prostate Cancer Nuclear Medicine Diagnostics Market Size by Country (2022-2027)
        6.4.3 United States
        6.4.4 Canada

7 Europe
    7.1 Europe Prostate Cancer Nuclear Medicine Diagnostics Market Size (2016-2027)
    7.2 Europe Prostate Cancer Nuclear Medicine Diagnostics Market Size by Type
        7.2.1 Europe Prostate Cancer Nuclear Medicine Diagnostics Market Size by Type (2016-2021)
        7.2.2 Europe Prostate Cancer Nuclear Medicine Diagnostics Market Size by Type (2022-2027)
        7.2.3 Europe Prostate Cancer Nuclear Medicine Diagnostics Market Size by Type (2016-2027)
    7.3 Europe Prostate Cancer Nuclear Medicine Diagnostics Market Size by Application
        7.3.1 Europe Prostate Cancer Nuclear Medicine Diagnostics Market Size by Application (2016-2021)
        7.3.2 Europe Prostate Cancer Nuclear Medicine Diagnostics Market Size by Application (2022-2027)
        7.3.3 Europe Prostate Cancer Nuclear Medicine Diagnostics Market Size by Application (2016-2027)
    7.4 Europe Prostate Cancer Nuclear Medicine Diagnostics Market Size by Country
        7.4.1 Europe Prostate Cancer Nuclear Medicine Diagnostics Market Size by Country (2016-2021)
        7.4.2 Europe Prostate Cancer Nuclear Medicine Diagnostics Market Size by Country (2022-2027)
        7.4.3 Germany
        7.4.4 France
        7.4.5 U.K.
        7.4.6 Italy
        7.4.7 Russia
        7.4.8 Nordic

8 Asia-Pacific
    8.1 Asia-Pacific Prostate Cancer Nuclear Medicine Diagnostics Market Size (2016-2027)
    8.2 Asia-Pacific Prostate Cancer Nuclear Medicine Diagnostics Market Size by Type
        8.2.1 Asia-Pacific Prostate Cancer Nuclear Medicine Diagnostics Market Size by Type (2016-2021)
        8.2.2 Asia-Pacific Prostate Cancer Nuclear Medicine Diagnostics Market Size by Type (2022-2027)
        8.2.3 Asia-Pacific Prostate Cancer Nuclear Medicine Diagnostics Market Size by Type (2016-2027)
    8.3 Asia-Pacific Prostate Cancer Nuclear Medicine Diagnostics Market Size by Application
        8.3.1 Asia-Pacific Prostate Cancer Nuclear Medicine Diagnostics Market Size by Application (2016-2021)
        8.3.2 Asia-Pacific Prostate Cancer Nuclear Medicine Diagnostics Market Size by Application (2022-2027)
        8.3.3 Asia-Pacific Prostate Cancer Nuclear Medicine Diagnostics Market Size by Application (2016-2027)
    8.4 Asia-Pacific Prostate Cancer Nuclear Medicine Diagnostics Market Size by Region
        8.4.1 Asia-Pacific Prostate Cancer Nuclear Medicine Diagnostics Market Size by Region (2016-2021)
        8.4.2 Asia-Pacific Prostate Cancer Nuclear Medicine Diagnostics Market Size by Region (2022-2027)
        8.4.3 China
        8.4.4 Japan
        8.4.5 South Korea
        8.4.6 Southeast Asia
        8.4.7 India
        8.4.8 Australia

9 Latin America
    9.1 Latin America Prostate Cancer Nuclear Medicine Diagnostics Market Size (2016-2027)
    9.2 Latin America Prostate Cancer Nuclear Medicine Diagnostics Market Size by Type
        9.2.1 Latin America Prostate Cancer Nuclear Medicine Diagnostics Market Size by Type (2016-2021)
        9.2.2 Latin America Prostate Cancer Nuclear Medicine Diagnostics Market Size by Type (2022-2027)
        9.2.3 Latin America Prostate Cancer Nuclear Medicine Diagnostics Market Size by Type (2016-2027)
    9.3 Latin America Prostate Cancer Nuclear Medicine Diagnostics Market Size by Application
        9.3.1 Latin America Prostate Cancer Nuclear Medicine Diagnostics Market Size by Application (2016-2021)
        9.3.2 Latin America Prostate Cancer Nuclear Medicine Diagnostics Market Size by Application (2022-2027)
        9.3.3 Latin America Prostate Cancer Nuclear Medicine Diagnostics Market Size by Application (2016-2027)
    9.4 Latin America Prostate Cancer Nuclear Medicine Diagnostics Market Size by Country
        9.4.1 Latin America Prostate Cancer Nuclear Medicine Diagnostics Market Size by Country (2016-2021)
        9.4.2 Latin America Prostate Cancer Nuclear Medicine Diagnostics Market Size by Country (2022-2027)
        9.4.3 Mexico
        9.4.4 Brazil

10 Middle East & Africa
    10.1 Middle East & Africa Prostate Cancer Nuclear Medicine Diagnostics Market Size (2016-2027)
    10.2 Middle East & Africa Prostate Cancer Nuclear Medicine Diagnostics Market Size by Type
        10.2.1 Middle East & Africa Prostate Cancer Nuclear Medicine Diagnostics Market Size by Type (2016-2021)
        10.2.2 Middle East & Africa Prostate Cancer Nuclear Medicine Diagnostics Market Size by Type (2022-2027)
        10.2.3 Middle East & Africa Prostate Cancer Nuclear Medicine Diagnostics Market Size by Type (2016-2027)
    10.3 Middle East & Africa Prostate Cancer Nuclear Medicine Diagnostics Market Size by Application
        10.3.1 Middle East & Africa Prostate Cancer Nuclear Medicine Diagnostics Market Size by Application (2016-2021)
        10.3.2 Middle East & Africa Prostate Cancer Nuclear Medicine Diagnostics Market Size by Application (2022-2027)
        10.3.3 Middle East & Africa Prostate Cancer Nuclear Medicine Diagnostics Market Size by Application (2016-2027)
    10.4 Middle East & Africa Prostate Cancer Nuclear Medicine Diagnostics Market Size by Country
        10.4.1 Middle East & Africa Prostate Cancer Nuclear Medicine Diagnostics Market Size by Country (2016-2021)
        10.4.2 Middle East & Africa Prostate Cancer Nuclear Medicine Diagnostics Market Size by Country (2022-2027)
        10.4.3 Turkey
        10.4.4 Saudi Arabia
        10.4.5 UAE

11 Key Players Profiles
    11.1 Blue Earth Diagnostics
        11.1.1 Blue Earth Diagnostics Company Details
        11.1.2 Blue Earth Diagnostics Business Overview
        11.1.3 Blue Earth Diagnostics Prostate Cancer Nuclear Medicine Diagnostics Introduction
        11.1.4 Blue Earth Diagnostics Revenue in Prostate Cancer Nuclear Medicine Diagnostics Business (2016-2021)
        11.1.5 Blue Earth Diagnostics Recent Development
    11.2 PETNET Solutions
        11.2.1 PETNET Solutions Company Details
        11.2.2 PETNET Solutions Business Overview
        11.2.3 PETNET Solutions Prostate Cancer Nuclear Medicine Diagnostics Introduction
        11.2.4 PETNET Solutions Revenue in Prostate Cancer Nuclear Medicine Diagnostics Business (2016-2021)
        11.2.5 PETNET Solutions Recent Development
    11.3 Cardinal Health
        11.3.1 Cardinal Health Company Details
        11.3.2 Cardinal Health Business Overview
        11.3.3 Cardinal Health Prostate Cancer Nuclear Medicine Diagnostics Introduction
        11.3.4 Cardinal Health Revenue in Prostate Cancer Nuclear Medicine Diagnostics Business (2016-2021)
        11.3.5 Cardinal Health Recent Development
    11.4 Lantheus Medical Imaging
        11.4.1 Lantheus Medical Imaging Company Details
        11.4.2 Lantheus Medical Imaging Business Overview
        11.4.3 Lantheus Medical Imaging Prostate Cancer Nuclear Medicine Diagnostics Introduction
        11.4.4 Lantheus Medical Imaging Revenue in Prostate Cancer Nuclear Medicine Diagnostics Business (2016-2021)
        11.4.5 Lantheus Medical Imaging Recent Development
    11.5 Jubilant Pharma
        11.5.1 Jubilant Pharma Company Details
        11.5.2 Jubilant Pharma Business Overview
        11.5.3 Jubilant Pharma Prostate Cancer Nuclear Medicine Diagnostics Introduction
        11.5.4 Jubilant Pharma Revenue in Prostate Cancer Nuclear Medicine Diagnostics Business (2016-2021)
        11.5.5 Jubilant Pharma Recent Development
    11.6 NCM-USA
        11.6.1 NCM-USA Company Details
        11.6.2 NCM-USA Business Overview
        11.6.3 NCM-USA Prostate Cancer Nuclear Medicine Diagnostics Introduction
        11.6.4 NCM-USA Revenue in Prostate Cancer Nuclear Medicine Diagnostics Business (2016-2021)
        11.6.5 NCM-USA Recent Development
    11.7 Progenics Pharma
        11.7.1 Progenics Pharma Company Details
        11.7.2 Progenics Pharma Business Overview
        11.7.3 Progenics Pharma Prostate Cancer Nuclear Medicine Diagnostics Introduction
        11.7.4 Progenics Pharma Revenue in Prostate Cancer Nuclear Medicine Diagnostics Business (2016-2021)
        11.7.5 Progenics Pharma Recent Development
    11.8 Telix Pharma
        11.8.1 Telix Pharma Company Details
        11.8.2 Telix Pharma Business Overview
        11.8.3 Telix Pharma Prostate Cancer Nuclear Medicine Diagnostics Introduction
        11.8.4 Telix Pharma Revenue in Prostate Cancer Nuclear Medicine Diagnostics Business (2016-2021)
        11.8.5 Telix Pharma Recent Development
    11.9 ImaginAb
        11.9.1 ImaginAb Company Details
        11.9.2 ImaginAb Business Overview
        11.9.3 ImaginAb Prostate Cancer Nuclear Medicine Diagnostics Introduction
        11.9.4 ImaginAb Revenue in Prostate Cancer Nuclear Medicine Diagnostics Business (2016-2021)
        11.9.5 ImaginAb Recent Development
    11.10 Theragnostics
        11.10.1 Theragnostics Company Details
        11.10.2 Theragnostics Business Overview
        11.10.3 Theragnostics Prostate Cancer Nuclear Medicine Diagnostics Introduction
        11.10.4 Theragnostics Revenue in Prostate Cancer Nuclear Medicine Diagnostics Business (2016-2021)
        11.10.5 Theragnostics Recent Development
    11.11 Novartis
        11.11.1 Novartis Company Details
        11.11.2 Novartis Business Overview
        11.11.3 Novartis Prostate Cancer Nuclear Medicine Diagnostics Introduction
        11.11.4 Novartis Revenue in Prostate Cancer Nuclear Medicine Diagnostics Business (2016-2021)
        11.11.5 Novartis Recent Development
    11.12 Alliance Medical
        11.12.1 Alliance Medical Company Details
        11.12.2 Alliance Medical Business Overview
        11.12.3 Alliance Medical Prostate Cancer Nuclear Medicine Diagnostics Introduction
        11.12.4 Alliance Medical Revenue in Prostate Cancer Nuclear Medicine Diagnostics Business (2016-2021)
        11.12.5 Alliance Medical Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix
    13.1 Research Methodology
        13.1.1 Methodology/Research Approach
        13.1.2 Data Source
    13.2 Disclaimer
    13.3 Author Details
List of Tables
    Table 1. Global Prostate Cancer Nuclear Medicine Diagnostics Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
    Table 2. Key Players of SPECT
    Table 3. Key Players of PET
    Table 4. Global Prostate Cancer Nuclear Medicine Diagnostics Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
    Table 5. Global Prostate Cancer Nuclear Medicine Diagnostics Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
    Table 6. Global Prostate Cancer Nuclear Medicine Diagnostics Market Size by Regions (2016-2021) & (US$ Million)
    Table 7. Global Prostate Cancer Nuclear Medicine Diagnostics Market Share by Regions (2016-2021)
    Table 8. Global Prostate Cancer Nuclear Medicine Diagnostics Forecasted Market Size by Regions (2022-2027) & (US$ Million)
    Table 9. Global Prostate Cancer Nuclear Medicine Diagnostics Market Share by Regions (2022-2027)
    Table 10. Prostate Cancer Nuclear Medicine Diagnostics Market Trends
    Table 11. Prostate Cancer Nuclear Medicine Diagnostics Market Drivers
    Table 12. Prostate Cancer Nuclear Medicine Diagnostics Market Challenges
    Table 13. Prostate Cancer Nuclear Medicine Diagnostics Market Restraints
    Table 14. Global Prostate Cancer Nuclear Medicine Diagnostics Revenue by Players (2016-2021) & (US$ Million)
    Table 15. Global Prostate Cancer Nuclear Medicine Diagnostics Market Share by Players (2016-2021)
    Table 16. Global Top Prostate Cancer Nuclear Medicine Diagnostics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Prostate Cancer Nuclear Medicine Diagnostics as of 2020)
    Table 17. Ranking of Global Top Prostate Cancer Nuclear Medicine Diagnostics Companies by Revenue (US$ Million) in 2020
    Table 18. Global 5 Largest Players Market Share by Prostate Cancer Nuclear Medicine Diagnostics Revenue (CR5 and HHI) & (2016-2021)
    Table 19. Key Players Headquarters and Area Served
    Table 20. Key Players Prostate Cancer Nuclear Medicine Diagnostics Product Solution and Service
    Table 21. Date of Enter into Prostate Cancer Nuclear Medicine Diagnostics Market
    Table 22. Mergers & Acquisitions, Expansion Plans
    Table 23. Global Prostate Cancer Nuclear Medicine Diagnostics Market Size by Type (2016-2021) (US$ Million)
    Table 24. Global Prostate Cancer Nuclear Medicine Diagnostics Revenue Market Share by Type (2016-2021)
    Table 25. Global Prostate Cancer Nuclear Medicine Diagnostics Forecasted Market Size by Type (2022-2027) (US$ Million)
    Table 26. Global Prostate Cancer Nuclear Medicine Diagnostics Revenue Market Share by Type (2022-2027) & (US$ Million)
    Table 27. Global Prostate Cancer Nuclear Medicine Diagnostics Market Size Share by Application (2016-2021) & (US$ Million)
    Table 28. Global Prostate Cancer Nuclear Medicine Diagnostics Revenue Market Share by Application (2016-2021)
    Table 29. Global Prostate Cancer Nuclear Medicine Diagnostics Forecasted Market Size by Application (2022-2027) (US$ Million)
    Table 30. Global Prostate Cancer Nuclear Medicine Diagnostics Revenue Market Share by Application (2022-2027) & (US$ Million)
    Table 31. North America Prostate Cancer Nuclear Medicine Diagnostics Market Size by Type (2016-2021) (US$ Million)
    Table 32. North America Prostate Cancer Nuclear Medicine Diagnostics Market Size by Type (2022-2027) & (US$ Million)
    Table 33. North America Prostate Cancer Nuclear Medicine Diagnostics Market Size by Application (2016-2021) (US$ Million)
    Table 34. North America Prostate Cancer Nuclear Medicine Diagnostics Market Size by Application (2022-2027) & (US$ Million)
    Table 35. North America Prostate Cancer Nuclear Medicine Diagnostics Market Size by Country (2016-2021) & (US$ Million) 
    Table 36. North America Prostate Cancer Nuclear Medicine Diagnostics Market Size by Country (2022-2027) & (US$ Million) 
    Table 37. Europe Prostate Cancer Nuclear Medicine Diagnostics Market Size by Type (2016-2021) (US$ Million)
    Table 38. Europe Prostate Cancer Nuclear Medicine Diagnostics Market Size by Type (2022-2027) & (US$ Million)
    Table 39. Europe Prostate Cancer Nuclear Medicine Diagnostics Market Size by Application (2016-2021) (US$ Million)
    Table 40. Europe Prostate Cancer Nuclear Medicine Diagnostics Market Size by Application (2022-2027) & (US$ Million)
    Table 41. Europe Prostate Cancer Nuclear Medicine Diagnostics Market Size by Country (2016-2021) & (US$ Million) 
    Table 42. Europe Prostate Cancer Nuclear Medicine Diagnostics Market Size by Country (2022-2027) & (US$ Million) 
    Table 43. Asia-Pacific Prostate Cancer Nuclear Medicine Diagnostics Market Size by Type (2016-2021) (US$ Million)
    Table 44. Asia-Pacific Prostate Cancer Nuclear Medicine Diagnostics Market Size by Type (2022-2027) & (US$ Million)
    Table 45. Asia-Pacific Prostate Cancer Nuclear Medicine Diagnostics Market Size by Application (2016-2021) (US$ Million)
    Table 46. Asia-Pacific Prostate Cancer Nuclear Medicine Diagnostics Market Size by Application (2022-2027) & (US$ Million)
    Table 47. Asia-Pacific Prostate Cancer Nuclear Medicine Diagnostics Market Size by Region (2016-2021) & (US$ Million) 
    Table 48. Asia-Pacific Prostate Cancer Nuclear Medicine Diagnostics Market Size by Region (2022-2027) & (US$ Million) 
    Table 49. Latin America Prostate Cancer Nuclear Medicine Diagnostics Market Size by Type (2016-2021) (US$ Million)
    Table 50. Latin America Prostate Cancer Nuclear Medicine Diagnostics Market Size by Type (2022-2027) & (US$ Million)
    Table 51. Latin America Prostate Cancer Nuclear Medicine Diagnostics Market Size by Application (2016-2021) (US$ Million)
    Table 52. Latin America Prostate Cancer Nuclear Medicine Diagnostics Market Size by Application (2022-2027) & (US$ Million)
    Table 53. Latin America Prostate Cancer Nuclear Medicine Diagnostics Market Size by Country (2016-2021) & (US$ Million) 
    Table 54. Latin America Prostate Cancer Nuclear Medicine Diagnostics Market Size by Country (2022-2027) & (US$ Million) 
    Table 55. Middle East & Africa Prostate Cancer Nuclear Medicine Diagnostics Market Size by Type (2016-2021) (US$ Million)
    Table 56. Middle East & Africa Prostate Cancer Nuclear Medicine Diagnostics Market Size by Type (2022-2027) & (US$ Million)
    Table 57. Middle East & Africa Prostate Cancer Nuclear Medicine Diagnostics Market Size by Application (2016-2021) (US$ Million)
    Table 58. Middle East & Africa Prostate Cancer Nuclear Medicine Diagnostics Market Size by Application (2022-2027) & (US$ Million)
    Table 59. Middle East & Africa Prostate Cancer Nuclear Medicine Diagnostics Market Size by Country (2016-2021) & (US$ Million) 
    Table 60. Middle East & Africa Prostate Cancer Nuclear Medicine Diagnostics Market Size by Country (2022-2027) & (US$ Million) 
    Table 61. Blue Earth Diagnostics Company Details
    Table 62. Blue Earth Diagnostics Business Overview
    Table 63. Blue Earth Diagnostics Prostate Cancer Nuclear Medicine Diagnostics Product
    Table 64. Blue Earth Diagnostics Revenue in Prostate Cancer Nuclear Medicine Diagnostics Business (2016-2021) & (US$ Million)
    Table 65. Blue Earth Diagnostics Recent Development
    Table 66. PETNET Solutions Company Details
    Table 67. PETNET Solutions Business Overview
    Table 68. PETNET Solutions Prostate Cancer Nuclear Medicine Diagnostics Product
    Table 69. PETNET Solutions Revenue in Prostate Cancer Nuclear Medicine Diagnostics Business (2016-2021) & (US$ Million)
    Table 70. PETNET Solutions Recent Development
    Table 71. Cardinal Health Company Details
    Table 72. Cardinal Health Business Overview
    Table 73. Cardinal Health Prostate Cancer Nuclear Medicine Diagnostics Product
    Table 74. Cardinal Health Revenue in Prostate Cancer Nuclear Medicine Diagnostics Business (2016-2021) & (US$ Million)
    Table 75. Cardinal Health Recent Development
    Table 76. Lantheus Medical Imaging Company Details
    Table 77. Lantheus Medical Imaging Business Overview
    Table 78. Lantheus Medical Imaging Prostate Cancer Nuclear Medicine Diagnostics Product
    Table 79. Lantheus Medical Imaging Revenue in Prostate Cancer Nuclear Medicine Diagnostics Business (2016-2021) & (US$ Million)
    Table 80. Lantheus Medical Imaging Recent Development
    Table 81. Jubilant Pharma Company Details
    Table 82. Jubilant Pharma Business Overview
    Table 83. Jubilant Pharma Prostate Cancer Nuclear Medicine Diagnostics Product
    Table 84. Jubilant Pharma Revenue in Prostate Cancer Nuclear Medicine Diagnostics Business (2016-2021) & (US$ Million)
    Table 85. Jubilant Pharma Recent Development
    Table 86. NCM-USA Company Details
    Table 87. NCM-USA Business Overview
    Table 88. NCM-USA Prostate Cancer Nuclear Medicine Diagnostics Product
    Table 89. NCM-USA Revenue in Prostate Cancer Nuclear Medicine Diagnostics Business (2016-2021) & (US$ Million)
    Table 90. NCM-USA Recent Development
    Table 91. Progenics Pharma Company Details
    Table 92. Progenics Pharma Business Overview
    Table 93. Progenics Pharma Prostate Cancer Nuclear Medicine Diagnostics Product
    Table 94. Progenics Pharma Revenue in Prostate Cancer Nuclear Medicine Diagnostics Business (2016-2021) & (US$ Million)
    Table 95. Progenics Pharma Recent Development
    Table 96. Telix Pharma Company Details
    Table 97. Telix Pharma Business Overview
    Table 98. Telix Pharma Revenue in Prostate Cancer Nuclear Medicine Diagnostics Business (2016-2021) & (US$ Million)
    Table 99. Telix Pharma Recent Development
    Table 100. ImaginAb Company Details
    Table 101. ImaginAb Business Overview
    Table 102. ImaginAb Prostate Cancer Nuclear Medicine Diagnostics Product
    Table 103. ImaginAb Revenue in Prostate Cancer Nuclear Medicine Diagnostics Business (2016-2021) & (US$ Million)
    Table 104. ImaginAb Recent Development
    Table 105. Theragnostics Company Details
    Table 106. Theragnostics Business Overview
    Table 107. Theragnostics Prostate Cancer Nuclear Medicine Diagnostics Product
    Table 108. Theragnostics Revenue in Prostate Cancer Nuclear Medicine Diagnostics Business (2016-2021) & (US$ Million)
    Table 109. Theragnostics Recent Development
    Table 110. Novartis Company Details
    Table 111. Novartis Business Overview
    Table 112. Novartis Prostate Cancer Nuclear Medicine Diagnostics Product
    Table 113. Novartis Revenue in Prostate Cancer Nuclear Medicine Diagnostics Business (2016-2021) & (US$ Million)
    Table 114. Novartis Recent Development
    Table 115. Alliance Medical Company Details
    Table 116. Alliance Medical Business Overview
    Table 117. Alliance Medical Prostate Cancer Nuclear Medicine Diagnostics Product
    Table 118. Alliance Medical Revenue in Prostate Cancer Nuclear Medicine Diagnostics Business (2016-2021) & (US$ Million)
    Table 119. Alliance Medical Recent Development
    Table 120. Research Programs/Design for This Report
    Table 121. Key Data Information from Secondary Sources
    Table 122. Key Data Information from Primary Sources
List of Figures
    Figure 1. Global Prostate Cancer Nuclear Medicine Diagnostics Market Share by Type: 2020 VS 2027
    Figure 2. SPECT Features
    Figure 3. PET Features
    Figure 4. Global Prostate Cancer Nuclear Medicine Diagnostics Market Share by Application: 2020 VS 2027
    Figure 5. Hospitals Case Studies
    Figure 6. Clinics Case Studies
    Figure 7. Others Case Studies
    Figure 8. Prostate Cancer Nuclear Medicine Diagnostics Report Years Considered
    Figure 9. Global Prostate Cancer Nuclear Medicine Diagnostics Market Size (US$ Million), Year-over-Year: 2016-2027
    Figure 10. Global Prostate Cancer Nuclear Medicine Diagnostics Market Size (US$ Million), 2016 VS 2021 VS 2027
    Figure 11. Global Prostate Cancer Nuclear Medicine Diagnostics Market Share by Regions: 2020 VS 2027
    Figure 12. Global Prostate Cancer Nuclear Medicine Diagnostics Market Share by Regions (2022-2027)
    Figure 13. Global Prostate Cancer Nuclear Medicine Diagnostics Market Share by Players in 2020
    Figure 14. Global Top Prostate Cancer Nuclear Medicine Diagnostics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Prostate Cancer Nuclear Medicine Diagnostics as of 2020
    Figure 15. The Top 10 and 5 Players Market Share by Prostate Cancer Nuclear Medicine Diagnostics Revenue in 2020
    Figure 16. Global Prostate Cancer Nuclear Medicine Diagnostics Revenue Market Share by Type (2016-2021)
    Figure 17. Global Prostate Cancer Nuclear Medicine Diagnostics Revenue Market Share by Type (2022-2027)
    Figure 18. North America Prostate Cancer Nuclear Medicine Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 19. North America Prostate Cancer Nuclear Medicine Diagnostics Market Share by Type (2016-2027)
    Figure 20. North America Prostate Cancer Nuclear Medicine Diagnostics Market Share by Application (2016-2027)
    Figure 21. North America Prostate Cancer Nuclear Medicine Diagnostics Market Share by Country (2016-2027)
    Figure 22. United States Prostate Cancer Nuclear Medicine Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 23. Canada Prostate Cancer Nuclear Medicine Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 24. Europe Prostate Cancer Nuclear Medicine Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 25. Europe Prostate Cancer Nuclear Medicine Diagnostics Market Share by Type (2016-2027)
    Figure 26. Europe Prostate Cancer Nuclear Medicine Diagnostics Market Share by Application (2016-2027)
    Figure 27. Europe Prostate Cancer Nuclear Medicine Diagnostics Market Share by Country (2016-2027)
    Figure 28. Germany Prostate Cancer Nuclear Medicine Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 29. France Prostate Cancer Nuclear Medicine Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 30. U.K. Prostate Cancer Nuclear Medicine Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 31. Italy Prostate Cancer Nuclear Medicine Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 32. Russia Prostate Cancer Nuclear Medicine Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 33. Nordic Prostate Cancer Nuclear Medicine Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 34. Asia-Pacific Prostate Cancer Nuclear Medicine Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 35. Asia-Pacific Prostate Cancer Nuclear Medicine Diagnostics Market Share by Type (2016-2027)
    Figure 36. Asia-Pacific Prostate Cancer Nuclear Medicine Diagnostics Market Share by Application (2016-2027)
    Figure 37. Asia-Pacific Prostate Cancer Nuclear Medicine Diagnostics Market Share by Region (2016-2027)
    Figure 38. China Prostate Cancer Nuclear Medicine Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 39. Japan Prostate Cancer Nuclear Medicine Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 40. South Korea Prostate Cancer Nuclear Medicine Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 41. Southeast Asia Prostate Cancer Nuclear Medicine Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 42. India Prostate Cancer Nuclear Medicine Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 43. Australia Prostate Cancer Nuclear Medicine Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 44. Latin America Prostate Cancer Nuclear Medicine Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 45. Latin America Prostate Cancer Nuclear Medicine Diagnostics Market Share by Type (2016-2027)
    Figure 46. Latin America Prostate Cancer Nuclear Medicine Diagnostics Market Share by Application (2016-2027)
    Figure 47. Latin America Prostate Cancer Nuclear Medicine Diagnostics Market Share by Country (2016-2027)
    Figure 48. Mexico Prostate Cancer Nuclear Medicine Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 49. Brazil Prostate Cancer Nuclear Medicine Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 50. Middle East & Africa Prostate Cancer Nuclear Medicine Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 51. Middle East & Africa Prostate Cancer Nuclear Medicine Diagnostics Market Share by Type (2016-2027)
    Figure 52. Middle East & Africa Prostate Cancer Nuclear Medicine Diagnostics Market Share by Application (2016-2027)
    Figure 53. Middle East & Africa Prostate Cancer Nuclear Medicine Diagnostics Market Share by Country (2016-2027)
    Figure 54. Turkey Prostate Cancer Nuclear Medicine Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 55. Saudi Arabia Prostate Cancer Nuclear Medicine Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 56. UAE Prostate Cancer Nuclear Medicine Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 57. Blue Earth Diagnostics Revenue Growth Rate in Prostate Cancer Nuclear Medicine Diagnostics Business (2016-2021)
    Figure 58. PETNET Solutions Revenue Growth Rate in Prostate Cancer Nuclear Medicine Diagnostics Business (2016-2021)
    Figure 59. Cardinal Health Revenue Growth Rate in Prostate Cancer Nuclear Medicine Diagnostics Business (2016-2021)
    Figure 60. Lantheus Medical Imaging Revenue Growth Rate in Prostate Cancer Nuclear Medicine Diagnostics Business (2016-2021)
    Figure 61. Jubilant Pharma Revenue Growth Rate in Prostate Cancer Nuclear Medicine Diagnostics Business (2016-2021)
    Figure 62. NCM-USA Revenue Growth Rate in Prostate Cancer Nuclear Medicine Diagnostics Business (2016-2021)
    Figure 63. Progenics Pharma Revenue Growth Rate in Prostate Cancer Nuclear Medicine Diagnostics Business (2016-2021)
    Figure 64. Telix Pharma Revenue Growth Rate in Prostate Cancer Nuclear Medicine Diagnostics Business (2016-2021)
    Figure 65. ImaginAb Revenue Growth Rate in Prostate Cancer Nuclear Medicine Diagnostics Business (2016-2021)
    Figure 66. Theragnostics Revenue Growth Rate in Prostate Cancer Nuclear Medicine Diagnostics Business (2016-2021)
    Figure 67. Novartis Revenue Growth Rate in Prostate Cancer Nuclear Medicine Diagnostics Business (2016-2021)
    Figure 68. Alliance Medical Revenue Growth Rate in Prostate Cancer Nuclear Medicine Diagnostics Business (2016-2021)
    Figure 69. Bottom-up and Top-down Approaches for This Report
    Figure 70. Data Triangulation
    Figure 71. Key Executives Interviewed
Please ask for List of Figures. Request Sample Report
Companies Included in Reports:
Blue Earth Diagnostics
PETNET Solutions
Cardinal Health
Lantheus Medical Imaging
Jubilant Pharma
NCM-USA
Progenics Pharma
Telix Pharma
ImaginAb
Theragnostics
Novartis
Alliance Medical
Frequently Asked Questions
Prostate Cancer Nuclear Medicine Diagnostics report offers great insights of the market and consumer data and their interpretation through various figures and graphs. Report has embedded global market and regional market deep analysis through various research methodologies. The report also offers great competitor analysis of the industries and highlights the key aspect of their business like success stories, market development and growth rate.
Prostate Cancer Nuclear Medicine Diagnostics report is categorised based on following features:
  1. Global Market Players
  2. Geopolitical regions
  3. Consumer Insights
  4. Technological advancement
  5. Historic and Future Analysis of the Market
Prostate Cancer Nuclear Medicine Diagnostics report is designed on the six basic aspects of analysing the market, which covers the SWOT and SWAR analysis like strength, weakness, opportunity, threat, aspirations and results. This methodology helps investors to reach on to the desired and correct decision to put their capital into the market.

Related Reports

Medical Writing

Medical writing requires knowledge of the drug development process, understanding of research met ... Read More